[1]Alves de Medeiros AK, Speeckaert R, Desmet E,et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases[J]. PLoS One, 2016, 11: e0164080.doi:10.1371/journal.pone.0164080. [2]Bergallo M, Accorinti M, Galliano I, et al. Expression of miRNA 155, FOXP3 and ROR gamma, in children with moderate and severe atopic dermatitis[J]. Giorn Ital Dermat V, 2020, 155: 168-172. [3]Sung YY, Kim HK. Crocin ameliorates atopic dermatitis symptoms by down regulation of Th2 response via blocking of NF-κB/STAT6 signaling pathways in mice[J]. Nutrients, 2018, 10: 1625. doi:10.3390/nu10111625. [4]Jin WY, Huang W, Chen LQ, et al. Topical application of JAK1/JAK2 inhibitor momelotinib exhibits significant anti-inflammatory responses in DNCB-induced atopic dermatitis model mice[J]. Int J Mol Sci, 2018, 19: 3793. doi:10.3390/ijms19123973. [5]Lee DY, Hwang CJ, Choi JY, et al. Inhibitory effect of carnosol on phthalic anhydride-induced atopic dermatitis via inhibition of STAT3[J]. Biomol Ther, 2017, 25: 535-544. [6]Choi DW, Jung SY, Shon DH, et al. Piperine ameliorates trimellitic anhydride-induced atopic dermatitis-like symptoms by suppressing Th2-mediated immune responses via inhibition of STAT6 phosphorylation[J]. Molecules, 2020, 25: 2186. doi:10.3390/molecules25092186. [7]Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis:systematic analysis and modelling study[J]. BMJ,2020, 369:m1590.doi:10.1136/bmj.m1590. [8]Johansen C, Rittig AH, Mose M, et al. STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes[J]. PLoS One, 2017, 12: e0176994.doi: 10.1371/journal.pone.0176994. [9]Qin X, Chen C, Zhang Y, et al. Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling[J]. Saudi Pharm J, 2017, 25: 620-624. [10]Kulling PM, Olson KC, Hamele CE, et al. Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia[J]. PLoS One, 2018, 13: e0193429. doi: 10.1371/journal.pone.0193429. [11]Crncˇec I, Modak M, Gordziel C, et al. STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer[J]. Mol Oncol, 2018, 12: 514-528. [12]Hu X, Yuan L, Ma T. Mechanisms of JAK-STAT signal-ing pathway mediated by CXCL8 gene silencing on epithelial-mesenchymal transition of human cutaneous melanoma cells[J]. Oncol Lett, 2020, 20: 1973-1981. [13]Zhou X, Yan T, Huang C,et al. Melanoma cell-secreted exosomal mir-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway[J]. J Exp Clin Cancer Res, 2018, 37: 242.doi:10.1186/s13046-018-0911-3. [14]Sim GC, Wu S, Jin L, et al. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2[J]. Oncotarget, 2016, 7: 36074-36091. [15]Morgan EL, Wasson CW, Hanson L, et al. STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle[J]. PLoS Pathog, 2018, 14: e1006975.doi:10.1371/journal.ppat.1006975. [16]Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis[J]. Mediat Inflamm, 2017, 67:6419.doi:10.1155/2017/6716419. [17]Dörner T, Tanaka Y, Petri MA, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways[J]. Lupus Sci Med, 2020, 7: e000424. doi:10.1136/lupus-2020-000424. [18]Maeda K, Kosugi T, Sato W, et al. CD147/basigin limits lupus nephritis and Th17 cell differentiation in mice by inhibiting the interleukin-6/STAT-3 pathway[J]. Arthritis Rheumatol, 2015, 67: 2185-2195. [19]Slight-Webb S, Guthridge JM, Chakravarty EF, et al. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients[J]. JCI Insight, 2019, 4: e124575. doi:10.1172/jci.insight.124575. [20]Park JS, Kim SM, Hwang SH, et al. Combinatory treatment using tacrolimus and a STAT3 inhibitor regulate Treg cells and plasma cells[J]. Int J Immunopath Ph, 2018, 32: 1-8. [21]Yoshida N, He F, Kyttaris VC. T cell-specific STAT3 deficiency abrogates lupus nephritis[J]. Lupus, 2019, 28: 1468-1472. [22]Conn KL, Wasson P, Mcfarlane S, et al. Novel role for protein inhibitor of activated STAT4 (PIAS4) in the restriction of Herpes Simplex Virus 1 by the cellular intrinsic antiviral immune response[J]. J Virol, 2016, 90: 4807-4826. |